BPMUF
Basilea Pharmaceutica AG
OTC Markets OTCPKUSDEQUITY
DELAYED
Buy
+40/100
Last price
76.25
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
76.25
Day high
77.40
Day low
77.40
Volume
100
Market cap
—
P/E (TTM)
—
52W range
59.29 – 77.40
Trailing performance
Returnvs SPY
1W
-1.49%
-3.4%
1M
-1.49%
-2.9%
3M
+26.50%
+23.1%
6M
+7.39%
-7.5%
YTD
+20.55%
+6.6%
1Y
+12.55%
-3.1%
3Y
+52.50%
-29.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on BPMUF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $232.38M | $208.54M | $157.63M | $147.76M | +11.4% |
| Operating revenue | $232.38M | $208.54M | $157.63M | $147.76M | +11.4% |
| Cost of revenue | $39.32M | $38.68M | $26.79M | $24.60M | +1.7% |
| Gross profit | $193.06M | $169.86M | $130.84M | $123.16M | +13.7% |
| Research & development | $105.89M | $77.14M | $77.85M | $73.80M | +37.3% |
| Selling, general & admin | $35.62M | $31.54M | $33.78M | $30.82M | +12.9% |
| Total operating expense | $141.51M | $108.69M | $111.64M | $104.62M | +30.2% |
| Operating income | $51.55M | $61.18M | $19.20M | $18.54M | -15.7% |
| Net interest income | -$2.09M | -$2.93M | -$9.51M | -$9.52M | +28.7% |
| Pre-tax income | $45.88M | $60.26M | $10.46M | $12.10M | -23.9% |
| Tax provision | $5.63M | -$17.33M | $10.00K | -$45.00K | +132.5% |
| Net income | $40.24M | $77.59M | $10.45M | $12.15M | -48.1% |
| Net income to common | $40.24M | $77.59M | $10.45M | $12.15M | -48.1% |
| Basic EPS | 3.29 | 6.42 | 0.87 | 1.02 | -48.8% |
| Diluted EPS | 3.14 | 5.83 | 0.86 | 1.02 | -46.1% |
| EBIT | $49.23M | $64.60M | $21.66M | $21.95M | -23.8% |
| EBITDA | $51.05M | $66.34M | $23.24M | $23.05M | -23.0% |
| Basic shares | 12.24M | 12.09M | 11.99M | 11.86M | +1.2% |
| Diluted shares | 13.68M | 13.86M | 12.14M | 11.94M | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $159.80M | $120.70M | $59.90M | $84.70M | — | +32.4% |
| Cash & short-term investments | $159.80M | $120.70M | $59.90M | $84.70M | — | +32.4% |
| Accounts receivable | $13.49M | $8.88M | $27.89M | $33.15M | — | +52.0% |
| Inventory | $21.56M | $31.61M | $26.41M | $24.24M | — | -31.8% |
| Total current assets | $251.73M | $220.91M | $152.15M | $175.36M | — | +14.0% |
| Property, plant & equipment | $18.20M | $19.00M | $20.60M | $21.60M | — | -4.2% |
| Goodwill & intangibles | $371.00K | $374.00K | $548.00K | $578.00K | — | -0.8% |
| Total assets | $282.00M | $257.76M | $173.29M | $220.85M | — | +9.4% |
| Total current liabilities | $49.22M | $45.56M | $47.59M | $74.85M | — | +8.0% |
| Current debt | — | $0 | $15.45M | $37.47M | $123.50M | — |
| Long-term debt | $75.44M | $95.91M | $95.45M | $131.36M | — | -21.3% |
| Total debt | $89.22M | $111.67M | $128.61M | $187.14M | — | -20.1% |
| Total liabilities | $154.06M | $176.76M | $183.29M | $241.56M | — | -12.8% |
| Retained earnings | -$882.57M | -$923.29M | -$1.00B | -$1.01B | — | +4.4% |
| Shareholder equity | $127.94M | $81.00M | -$10.00M | -$20.71M | — | +58.0% |
| Working capital | $202.51M | $175.35M | $104.55M | $100.51M | — | +15.5% |
| Net tangible assets | $127.57M | $80.63M | -$10.55M | -$21.29M | — | +58.2% |
| Shares issued | 13.32M | 13.17M | 13.10M | 13.09M | — | +1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $40.24M | $77.59M | $10.45M | $12.15M | — | -48.1% |
| Depreciation & amortisation | $1.81M | $1.73M | $1.58M | $1.10M | — | +4.7% |
| Stock-based compensation | $5.24M | $5.07M | $4.76M | $3.60M | — | +3.4% |
| Change in working capital | $6.61M | $9.37M | -$5.22M | -$11.38M | — | -29.5% |
| Operating cash flow | $62.09M | $74.36M | $14.24M | $7.06M | — | -16.5% |
| Capital expenditure | -$2.86M | -$1.79M | -$1.03M | -$3.30M | — | -59.7% |
| Investing cash flow | -$2.86M | -$1.01M | -$1.03M | $91.65M | — | -183.1% |
| Share buybacks | — | $0 | -$381.00K | — | -$4.25M | — |
| Financing cash flow | -$21.43M | -$13.16M | -$57.30M | -$45.25M | — | -62.8% |
| Free cash flow | $59.23M | $72.57M | $13.21M | $3.75M | — | -18.4% |
| End cash position | $162.34M | $124.56M | $64.32M | $108.57M | — | +30.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $173.05M | $159.80M | $128.37M | +8.3% |
| Cash & short-term investments | $173.05M | $159.80M | — | +8.3% |
| Accounts receivable | $13.88M | $13.49M | — | +2.9% |
| Inventory | $26.04M | $21.56M | — | +20.8% |
| Total current assets | $273.81M | $251.73M | $217.47M | +8.8% |
| Property, plant & equipment | $16.70M | $18.20M | $17.50M | -8.2% |
| Goodwill & intangibles | $228.00K | $371.00K | $300.00K | -38.5% |
| Total assets | $298.04M | $282.00M | $248.85M | +5.7% |
| Total current liabilities | $41.51M | $49.22M | — | -15.7% |
| Long-term debt | $70.64M | $75.44M | $81.98M | -6.4% |
| Total debt | $83.44M | — | — | — |
| Total liabilities | $135.69M | $154.06M | — | -11.9% |
| Retained earnings | -$854.62M | -$882.57M | — | +3.2% |
| Shareholder equity | $162.35M | $127.94M | — | +26.9% |
| Working capital | $232.29M | $202.51M | — | +14.7% |
| Net tangible assets | $162.12M | $127.57M | $102.86M | +27.1% |
| Shares issued | 12.38M | 13.32M | 13.31M | -7.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
77.06
-1.04% from price
SMA 20
77.23
-1.27% from price
SMA 50
73.06
+4.37% from price
SMA 100
67.61
+12.78% from price
SMA 200
68.63
+11.10% from price
EMA 12
76.90
-0.85% from price
EMA 26
76.15
+0.14% from price
EMA 50
73.64
+3.54% from price
RSI (14)
54.9
Neutral
MACD (12,26,9)
0.76
Hist -0.51
ATR (14)
0.08
0.11% of price
Realised vol 30D
4.3%
Annualised
Bollinger upper
78.05
20, 2σ
Bollinger lower
76.41
20, 2σ
50 / 200 cross
Golden
73.06 vs 68.63
Trend bias
Above 200
+11.10%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.04
Less volatile than market
Correlation to SPY
-0.02
Largely independent
Realised vol 30D
4.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-18.5%
Peak to trough
Max drawdown 5Y
-25.8%
Peak to trough
ATR 14
0.08
0.11% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
GlobeNewswire · 24d ago
Basilea Pharmaceutica (SWX:BSLN) Lifts Guidance Following Strong Half Year Results, Is It Fully Valued?
Simply Wall St. · 47d ago
Basilea Pharmaceutica Ltd (XSWX:BSLN) (H1 2026) Earnings Call Highlights: Revenue Surges 14% ...
GuruFocus.com · 50d ago
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
GlobeNewswire · 51d ago
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
GlobeNewswire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.